DiMaggio E. Pharmacotherapy 2020.
Acute graft versus host disease (GVHD) remains a devastating complication following hematopoietic cell transplantation (HCT) resulting in increased morbidity and mortality. Vast research efforts continue to refine or develop new means of prediction, assessment, prevention, and treatment of this syndrome. Recent updates in acute GVHD include more definitive guidance and definitions for its grading and diagnosis. Biomarker utilization is being incorporated into early stages following HCT to aid in detection and prediction of long term outcomes. New preventative strategies under investigation include use of vedolizumab or tocilizumab as upfront prophylaxis. Finally, while steroids remain the backbone of therapy once treatment is warranted, efficacy of several agents including vedolizumab, tocilizumab, ruxolitinib, and alpha-1 antitrypsin are being evaluated as potential therapeutic options.